NCT01364051 2026-03-18
Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
10 trialsNCT06502171 2026-03-12
NF113
University of Alabama at Birmingham
Phase 1 Not yet recruiting
NCT05101148 2026-02-23
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
AstraZeneca
Phase 1 Active not recruiting
NCT02143466 2026-01-30
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
AstraZeneca
Phase 1 Active not recruiting
NCT04590235 2026-01-30
A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
AstraZeneca
Phase 1 Active not recruiting
NCT02546661 2025-12-29
BISCAY
AstraZeneca
Phase 1 Active not recruiting
NCT03326310 2025-12-29
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
University of Chicago
Phase 1 Recruiting
NCT00463814 2025-11-13
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies
AstraZeneca
Phase 1 Active not recruiting
NCT00600496 2025-11-13
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Active not recruiting
NCT03162627 2025-10-14
Selumetinib and Olaparib in Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting